Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients

Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Fabian Doerr [verfasserIn] Tobias Leschczyk [verfasserIn] Konstantinos Grapatsas [verfasserIn] Hruy Menghesha [verfasserIn] Natalie Baldes [verfasserIn] Georg Schlachtenberger [verfasserIn] Matthias B. Heldwein [verfasserIn] Maximilian Michel [verfasserIn] Alexander Quaas [verfasserIn] Lars Hagmeyer [verfasserIn] Katja Höpker [verfasserIn] Thorsten Wahlers [verfasserIn] Kaid Darwiche [verfasserIn] Christian Taube [verfasserIn] Martin Schuler [verfasserIn] Khosro Hekmat [verfasserIn] Servet Bölükbas [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2024

Schlagwörter:	non-small-cell lung cancer lobectomy lung capacity life quality long-term survival smoking cessation

Übergeordnetes Werk:	In: Cancers - MDPI AG, 2010, 16(2024), 2, p 465
Übergeordnetes Werk:	volume:16 ; year:2024 ; number:2, p 465

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/cancers16020465

Katalog-ID:	DOAJ096382678

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ096382678
003	DE-627
005	20240413150857.0
007	cr uuu---uuuuu
008	240413s2024 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/cancers16020465 \|2 doi
035			\|a (DE-627)DOAJ096382678
035			\|a (DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Fabian Doerr \|e verfasserin \|4 aut
245	1	0	\|a Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients
264		1	\|c 2024
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program.
650		4	\|a non-small-cell lung cancer
650		4	\|a lobectomy
650		4	\|a lung capacity
650		4	\|a life quality
650		4	\|a long-term survival
650		4	\|a smoking cessation
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Tobias Leschczyk \|e verfasserin \|4 aut
700	0		\|a Konstantinos Grapatsas \|e verfasserin \|4 aut
700	0		\|a Hruy Menghesha \|e verfasserin \|4 aut
700	0		\|a Natalie Baldes \|e verfasserin \|4 aut
700	0		\|a Georg Schlachtenberger \|e verfasserin \|4 aut
700	0		\|a Matthias B. Heldwein \|e verfasserin \|4 aut
700	0		\|a Maximilian Michel \|e verfasserin \|4 aut
700	0		\|a Alexander Quaas \|e verfasserin \|4 aut
700	0		\|a Lars Hagmeyer \|e verfasserin \|4 aut
700	0		\|a Katja Höpker \|e verfasserin \|4 aut
700	0		\|a Thorsten Wahlers \|e verfasserin \|4 aut
700	0		\|a Kaid Darwiche \|e verfasserin \|4 aut
700	0		\|a Christian Taube \|e verfasserin \|4 aut
700	0		\|a Martin Schuler \|e verfasserin \|4 aut
700	0		\|a Khosro Hekmat \|e verfasserin \|4 aut
700	0		\|a Servet Bölükbas \|e verfasserin \|4 aut
773	0	8	\|i In \|t Cancers \|d MDPI AG, 2010 \|g 16(2024), 2, p 465 \|w (DE-627)614095670 \|w (DE-600)2527080-1 \|x 20726694 \|7 nnns
773	1	8	\|g volume:16 \|g year:2024 \|g number:2, p 465
856	4	0	\|u https://doi.org/10.3390/cancers16020465 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2072-6694/16/2/465 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2072-6694 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 16 \|j 2024 \|e 2, p 465

Indexfelder

author_variant	f d fd t l tl k g kg h m hm n b nb g s gs m b h mbh m m mm a q aq l h lh k h kh t w tw k d kd c t ct m s ms k h kh s b sb
matchkey_str	article:20726694:2024----::otprtvtbcoestoipoeqaiyfieugucinnlntrsriain
hierarchy_sort_str	2024
callnumber-subject-code	RC
publishDate	2024
allfields	10.3390/cancers16020465 doi (DE-627)DOAJ096382678 (DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c DE-627 ger DE-627 rakwb eng RC254-282 Fabian Doerr verfasserin aut Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. non-small-cell lung cancer lobectomy lung capacity life quality long-term survival smoking cessation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tobias Leschczyk verfasserin aut Konstantinos Grapatsas verfasserin aut Hruy Menghesha verfasserin aut Natalie Baldes verfasserin aut Georg Schlachtenberger verfasserin aut Matthias B. Heldwein verfasserin aut Maximilian Michel verfasserin aut Alexander Quaas verfasserin aut Lars Hagmeyer verfasserin aut Katja Höpker verfasserin aut Thorsten Wahlers verfasserin aut Kaid Darwiche verfasserin aut Christian Taube verfasserin aut Martin Schuler verfasserin aut Khosro Hekmat verfasserin aut Servet Bölükbas verfasserin aut In Cancers MDPI AG, 2010 16(2024), 2, p 465 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:16 year:2024 number:2, p 465 https://doi.org/10.3390/cancers16020465 kostenfrei https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c kostenfrei https://www.mdpi.com/2072-6694/16/2/465 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2024 2, p 465
spelling	10.3390/cancers16020465 doi (DE-627)DOAJ096382678 (DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c DE-627 ger DE-627 rakwb eng RC254-282 Fabian Doerr verfasserin aut Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. non-small-cell lung cancer lobectomy lung capacity life quality long-term survival smoking cessation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tobias Leschczyk verfasserin aut Konstantinos Grapatsas verfasserin aut Hruy Menghesha verfasserin aut Natalie Baldes verfasserin aut Georg Schlachtenberger verfasserin aut Matthias B. Heldwein verfasserin aut Maximilian Michel verfasserin aut Alexander Quaas verfasserin aut Lars Hagmeyer verfasserin aut Katja Höpker verfasserin aut Thorsten Wahlers verfasserin aut Kaid Darwiche verfasserin aut Christian Taube verfasserin aut Martin Schuler verfasserin aut Khosro Hekmat verfasserin aut Servet Bölükbas verfasserin aut In Cancers MDPI AG, 2010 16(2024), 2, p 465 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:16 year:2024 number:2, p 465 https://doi.org/10.3390/cancers16020465 kostenfrei https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c kostenfrei https://www.mdpi.com/2072-6694/16/2/465 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2024 2, p 465
allfields_unstemmed	10.3390/cancers16020465 doi (DE-627)DOAJ096382678 (DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c DE-627 ger DE-627 rakwb eng RC254-282 Fabian Doerr verfasserin aut Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. non-small-cell lung cancer lobectomy lung capacity life quality long-term survival smoking cessation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tobias Leschczyk verfasserin aut Konstantinos Grapatsas verfasserin aut Hruy Menghesha verfasserin aut Natalie Baldes verfasserin aut Georg Schlachtenberger verfasserin aut Matthias B. Heldwein verfasserin aut Maximilian Michel verfasserin aut Alexander Quaas verfasserin aut Lars Hagmeyer verfasserin aut Katja Höpker verfasserin aut Thorsten Wahlers verfasserin aut Kaid Darwiche verfasserin aut Christian Taube verfasserin aut Martin Schuler verfasserin aut Khosro Hekmat verfasserin aut Servet Bölükbas verfasserin aut In Cancers MDPI AG, 2010 16(2024), 2, p 465 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:16 year:2024 number:2, p 465 https://doi.org/10.3390/cancers16020465 kostenfrei https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c kostenfrei https://www.mdpi.com/2072-6694/16/2/465 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2024 2, p 465
allfieldsGer	10.3390/cancers16020465 doi (DE-627)DOAJ096382678 (DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c DE-627 ger DE-627 rakwb eng RC254-282 Fabian Doerr verfasserin aut Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. non-small-cell lung cancer lobectomy lung capacity life quality long-term survival smoking cessation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tobias Leschczyk verfasserin aut Konstantinos Grapatsas verfasserin aut Hruy Menghesha verfasserin aut Natalie Baldes verfasserin aut Georg Schlachtenberger verfasserin aut Matthias B. Heldwein verfasserin aut Maximilian Michel verfasserin aut Alexander Quaas verfasserin aut Lars Hagmeyer verfasserin aut Katja Höpker verfasserin aut Thorsten Wahlers verfasserin aut Kaid Darwiche verfasserin aut Christian Taube verfasserin aut Martin Schuler verfasserin aut Khosro Hekmat verfasserin aut Servet Bölükbas verfasserin aut In Cancers MDPI AG, 2010 16(2024), 2, p 465 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:16 year:2024 number:2, p 465 https://doi.org/10.3390/cancers16020465 kostenfrei https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c kostenfrei https://www.mdpi.com/2072-6694/16/2/465 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2024 2, p 465
allfieldsSound	10.3390/cancers16020465 doi (DE-627)DOAJ096382678 (DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c DE-627 ger DE-627 rakwb eng RC254-282 Fabian Doerr verfasserin aut Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. non-small-cell lung cancer lobectomy lung capacity life quality long-term survival smoking cessation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tobias Leschczyk verfasserin aut Konstantinos Grapatsas verfasserin aut Hruy Menghesha verfasserin aut Natalie Baldes verfasserin aut Georg Schlachtenberger verfasserin aut Matthias B. Heldwein verfasserin aut Maximilian Michel verfasserin aut Alexander Quaas verfasserin aut Lars Hagmeyer verfasserin aut Katja Höpker verfasserin aut Thorsten Wahlers verfasserin aut Kaid Darwiche verfasserin aut Christian Taube verfasserin aut Martin Schuler verfasserin aut Khosro Hekmat verfasserin aut Servet Bölükbas verfasserin aut In Cancers MDPI AG, 2010 16(2024), 2, p 465 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:16 year:2024 number:2, p 465 https://doi.org/10.3390/cancers16020465 kostenfrei https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c kostenfrei https://www.mdpi.com/2072-6694/16/2/465 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2024 2, p 465
language	English
source	In Cancers 16(2024), 2, p 465 volume:16 year:2024 number:2, p 465
sourceStr	In Cancers 16(2024), 2, p 465 volume:16 year:2024 number:2, p 465
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	non-small-cell lung cancer lobectomy lung capacity life quality long-term survival smoking cessation Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Cancers
authorswithroles_txt_mv	Fabian Doerr @@aut@@ Tobias Leschczyk @@aut@@ Konstantinos Grapatsas @@aut@@ Hruy Menghesha @@aut@@ Natalie Baldes @@aut@@ Georg Schlachtenberger @@aut@@ Matthias B. Heldwein @@aut@@ Maximilian Michel @@aut@@ Alexander Quaas @@aut@@ Lars Hagmeyer @@aut@@ Katja Höpker @@aut@@ Thorsten Wahlers @@aut@@ Kaid Darwiche @@aut@@ Christian Taube @@aut@@ Martin Schuler @@aut@@ Khosro Hekmat @@aut@@ Servet Bölükbas @@aut@@
publishDateDaySort_date	2024-01-01T00:00:00Z
hierarchy_top_id	614095670
id	DOAJ096382678
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ096382678</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413150857.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2024 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers16020465</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ096382678</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Fabian Doerr</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">non-small-cell lung cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lobectomy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lung capacity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">life quality</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">long-term survival</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">smoking cessation</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tobias Leschczyk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Konstantinos Grapatsas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hruy Menghesha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natalie Baldes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Georg Schlachtenberger</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matthias B. Heldwein</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maximilian Michel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexander Quaas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lars Hagmeyer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katja Höpker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thorsten Wahlers</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kaid Darwiche</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christian Taube</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martin Schuler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Khosro Hekmat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Servet Bölükbas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">16(2024), 2, p 465</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:2, p 465</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers16020465</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/16/2/465</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2024</subfield><subfield code="e">2, p 465</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Fabian Doerr
spellingShingle	Fabian Doerr misc RC254-282 misc non-small-cell lung cancer misc lobectomy misc lung capacity misc life quality misc long-term survival misc smoking cessation misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients
authorStr	Fabian Doerr
ppnlink_with_tag_str_mv	@@773@@(DE-627)614095670
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	20726694
topic_title	RC254-282 Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients non-small-cell lung cancer lobectomy lung capacity life quality long-term survival smoking cessation
topic	misc RC254-282 misc non-small-cell lung cancer misc lobectomy misc lung capacity misc life quality misc long-term survival misc smoking cessation misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc non-small-cell lung cancer misc lobectomy misc lung capacity misc life quality misc long-term survival misc smoking cessation misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc non-small-cell lung cancer misc lobectomy misc lung capacity misc life quality misc long-term survival misc smoking cessation misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Cancers
hierarchy_parent_id	614095670
hierarchy_top_title	Cancers
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)614095670 (DE-600)2527080-1
title	Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients
ctrlnum	(DE-627)DOAJ096382678 (DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c
title_full	Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients
author_sort	Fabian Doerr
journal	Cancers
journalStr	Cancers
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2024
contenttype_str_mv	txt
author_browse	Fabian Doerr Tobias Leschczyk Konstantinos Grapatsas Hruy Menghesha Natalie Baldes Georg Schlachtenberger Matthias B. Heldwein Maximilian Michel Alexander Quaas Lars Hagmeyer Katja Höpker Thorsten Wahlers Kaid Darwiche Christian Taube Martin Schuler Khosro Hekmat Servet Bölükbas
container_volume	16
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Fabian Doerr
doi_str_mv	10.3390/cancers16020465
author2-role	verfasserin
title_sort	postoperative tobacco cessation improves quality of life, lung function and long-term survival in non-small-cell lung cancer patients
callnumber	RC254-282
title_auth	Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients
abstract	Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program.
abstractGer	Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program.
abstract_unstemmed	Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2, p 465
title_short	Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients
url	https://doi.org/10.3390/cancers16020465 https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c https://www.mdpi.com/2072-6694/16/2/465 https://doaj.org/toc/2072-6694
remote_bool	true
author2	Tobias Leschczyk Konstantinos Grapatsas Hruy Menghesha Natalie Baldes Georg Schlachtenberger Matthias B. Heldwein Maximilian Michel Alexander Quaas Lars Hagmeyer Katja Höpker Thorsten Wahlers Kaid Darwiche Christian Taube Martin Schuler Khosro Hekmat Servet Bölükbas
author2Str	Tobias Leschczyk Konstantinos Grapatsas Hruy Menghesha Natalie Baldes Georg Schlachtenberger Matthias B. Heldwein Maximilian Michel Alexander Quaas Lars Hagmeyer Katja Höpker Thorsten Wahlers Kaid Darwiche Christian Taube Martin Schuler Khosro Hekmat Servet Bölükbas
ppnlink	614095670
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/cancers16020465
callnumber-a	RC254-282
up_date	2024-07-03T19:51:54.779Z
_version_	1803588798810947584
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ096382678</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413150857.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2024 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers16020465</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ096382678</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Fabian Doerr</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">non-small-cell lung cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lobectomy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lung capacity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">life quality</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">long-term survival</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">smoking cessation</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tobias Leschczyk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Konstantinos Grapatsas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hruy Menghesha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natalie Baldes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Georg Schlachtenberger</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matthias B. Heldwein</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maximilian Michel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexander Quaas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lars Hagmeyer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katja Höpker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thorsten Wahlers</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kaid Darwiche</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christian Taube</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martin Schuler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Khosro Hekmat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Servet Bölükbas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">16(2024), 2, p 465</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:2, p 465</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers16020465</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/16/2/465</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2024</subfield><subfield code="e">2, p 465</subfield></datafield></record></collection>
score	7.3998823

Nicht das Richtige dabei?

Schreiben Sie uns!

Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?